7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine

Psychopharmacology

Volumn 231, Issue 1, 2014, Pages 159-166

  Ren, Qian ^a   Zhang, Ji Chun ^a   Ma, Min ^a   Fujita, Yuko ^a   Wu, Jin ^a   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

7,8 Dihydroxyflavone; ANA 12; Behavioral sensitization; Dopamine; Methamphetamine; Microglial activation; Neurotoxicity; TrkB agonist

Indexed keywords

7,8 DIHYDROXYFLAVONE; ANA 12; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; DOPAMINE TRANSPORTER; METHAMPHETAMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CELL ACTIVATION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ABUSE; DRUG INHIBITION; DRUG REEXPOSURE; HYPERACTIVITY; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FLAVONES; FLAVONOIDS; IMMUNOHISTOCHEMISTRY; MALE; METHAMPHETAMINE; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; NEOSTRIATUM; NEUROTOXICITY SYNDROMES; RECEPTOR, TRKB;

EID: 84891830653     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3221-7     Document Type: Article

References (43)

1. Albers DS, Sonsalla PK (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 274:1104-1114
2. Ali SF, Newport GD, Slikker W Jr (1996) Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents. Ann NY Acad Sci 801:187-198
3. Andero R, Heldt SA, Ye K, Liu X, Armario A, Ressler KJ (2011) Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, in emotional learning. Am J Psychiatry 168:163-172
4. Barr A, Panenka W, MacEwan W, Thornton AE, Lang DJ, Honer WG, Lecomte T (2006) The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 31:301-313
5. Berhow MT, Russell DS, Terwilliger RZ, Beitner-Johnson D, Self DS, Lindsay RM, Nestler EJ (1995) Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopamine system. Neuroscience 68:969-979
6. Blugeot A, Rivat C, Bouvier E, Molet J, Mouchard A, Zeau B, Bernard C, Benoliel JJ, Becker C (2011) Vulnerability to depression: from brain neuroplasticity to identification of biomarkers. J Neurosci 31:12889-12899
7. Cadet JL, Jayanthi S, Deng X (2003) Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17:1775-1788
8. Chen H, Wu J, Zhang JC, Hashimoto K (2010) Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence. Curr Drug Abuse Rev 3:222-238
9. Chen H, Wu J, Zhang J, Fujita Y, Ishima T, Iyo M, Hashimoto K (2011) Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine. Psychopharmacology (Berl) 222:37-45
10. Chen PH, Huang MC, Lai YC, Chen PY, Liu HC (2013) Serum brain-derived neurotrophic factor levels were reduced during methamphetamine early withdrawal. Addiction Biol doi: 10.1111/j.1369-1600.2012.00444.x (in press)
11. Colfax G, Santos GM, Chu P, Vittinghoff E, Pluddemann A, Kumar S, Hart C (2010) Amphetamine-group substances and HIV. Lancet 376:458-474
12. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 6:1-22
13. Dean AC, Groman SM, Morales AM, London ED (2013) An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology 38:259-274
14. Devi L, Ohno M (2012) 7,8-Dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology 37:434-444
15. Franklin KBJ, Paxinos G (1997) The mouse brain in the stereotaxic coordinates. Academic, San Diego
16. Gonzales R, Mooney L, Rawson RA (2010) The methamphetamine problem in the United States. Annu Rev Public Health 31:385-398
17. Graham DL, Krishnan V, Larson EB, Graham A, Edwards S, Bachtell RK, Simmons D, Gent LM, Berton O, Bolanos CA, DiLeone RJ, Parada LF, Nestler EJ, Self DW (2009) Tropomyosin-related kinase B in the mesolimbic dopamine system: region-specific effects on cocaine reward. Biol Psychiatry 65:696-701
18. Guilarte TR, Nihei MK, McGlothan JL, Howard AS (2003) Methamphetamine induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 122:499-513
19. Hagiwara H, Iyo M, Hashimoto K (2009) Mithramycin protects against dopaminergic neurotoxicity in the mouse brain after administration of methamphetamine. Brain Res 1301:189-196
20. Hashimoto K (2007) New research on methamphetamine abuse. In: Toolaney GH (ed) New research on methamphetamine abuse. NovaScience, New York, pp 1-51
21. Hashimoto K (2013) Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 100:15-29
22. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, Wilson WD, Xiao G, Blanchi B, Sun YE, Ye K (2010) A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA 107:2687-2692
23. Kita T, Paku S, Takahashi M, Kubo K, Wagner GC, Nakashima T (1998) Methamphetamine-induced neurotoxicity in BALB/c, DBA/2N and C57BL/6N mice. Neuropharmacology 37:1177-1784
24. Koike K, Hashimoto K, Fukami G, Okamura N, Zhang L, Zhang L, Ohgake S, Koizumi H, Matsuzawa D, Kawamura N, Shimizu E, Iyo M (2005) The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Neuropharmacology 48:391-397
25. LaVoie MJ, Card JP, Hastings TG (2004) Microglia activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 187:47-57
26. Liu X, Chan CB, Jang SW, Pradoldej S, Huang J, He K, Phun LH, France S, Xiao G, Jia Y, Luo HR, Ye K (2010) A Synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect. J Med Chem 53:8274-8286
27. Lobo MK, Covington HE 3rd, Chaudhury D, Friedman AK, Sun H, Damez-Werno D, Dietz DM, Zaman S, Koo JW, Kennedy PJ, Mouzon E, Mogri M, Neve RL, Deisseroth K, Han MH, Nestler EJ (2010) Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science 330:385-390
28. McGinty JF, Bache AJ, Coleman NT, Sun WL (2011) The role of BDNF/TrkB signaling in acute amphetamine-induced locomotor activity and opioid peptide gene expression in the rat dorsal striatum. Front Syst Neurosci 5:60
29. Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T (2003) Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 119:767-775
30. National Institute on Drug Abuse (2002) Research report series - methamphetamine abuse and addiction. NIDA, Rockville
31. Pierce RC, Kalivas PW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 25:192-216
32. Ren Q, Zhang JC, Fujita Y, Ma M, Wu J, Hashimoto K (2013) Effects of TrkB agonist 7,8-dihydroxyflavone on sensory gating deficits in mice after administration of methamphetamine. Pharmacol Biochem Behav 106:124-127
33. Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157-198
34. Russo SJ, Mazei-Robison MS, Ables JL, Nestler EJ (2009) Neurotrophic factors and structural plasticity in addiction. Neuropharmacology 56:73-82
35. Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33:639-677
36. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futabayashi M, Takei N, Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214
37. Thomas DM, Kuhn DM (2005) Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J Neurochem 92:790-797
38. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglia activation. J Pharmacol Exp Ther 311:1-7
39. Vanderschuren LJ, Kalivas PW (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 151:99-120
40. Volkow ND, Chang L, Wang GJ, Folwer JS, Ding YS, Sedler M, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382
41. White FJ, Kalivas PW (1998) Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 51:141-153
42. Wilson JM, Kalansinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703
43. Zhang L, Kitaichi K, Fujimoto Y, Nakayama H, Shimizu E, Iyo M, Hashimoto K (2006) Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuro-Psychopharmacol Biol Psychiatry 30:1381-1393